Esperion Theraptc (ESPR) Stock Price, Quote & News

Company Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovasc...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 734 887 3903

Website: www.esperion.com

Address:

3891 Ranchero Drive, Suite 150, Ann Arbor, United States

Rustyton Jan. 14 at 5:37 AM

$ESPR blockbuster drug, scam stock with constant fuckery. I never thought we’d go lower than $1.50 last year, but there we were at $0.69. The sp will go as high or low as they want it to go but there’s no question where this is heading long term. Revenue will be pouring in from all over in a couple years and then triple combo hits the market. Sheldon should be pushing Vision 2028 or 2030 at the latest… telling investors they’ll be worth billions by then and a cash cow through the 2030’s with a pipeline that could also be worth billions

1 · Reply

MoneyGroupLLC Jan. 14 at 5:23 AM

Enter: $ESPR Calls Strike Price: $4 Expiry Date: FEB 20 2026 Buy in Price: $0.30 - $1.00 Sell Price: $0.48 Profit : +60% (Turn every $1 into $1.60) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

littleguyfinance Jan. 14 at 5:15 AM

$ESPR after ranting this week, I wanted to offset my negativity with some positive words. I greatly appreciate the DD and insight shared on this board over the years. DJ, Omar, Logan, Dave, Maxhappy, Skipper, Gregg, Gary, and many more. I am up big on my ESPR position and your posts helped give me courage to average down heavily below $1. I am holding a very large position that is uncomfortable for me, yet I am willing to take the risk because I believe in the DD that I have done, supplemented by many of you on this board. Thank you.

1 · Reply

Moneo Jan. 14 at 4:31 AM

$ESPR do I look scared MFer?

0 · Reply

Adam_W Jan. 14 at 4:24 AM

$ESPR Haven’t sold a single share….

0 · Reply

simbha Jan. 14 at 3:38 AM

$ESPR I am expecting this to bounce back to 3.61 by Friday. Back in the channel and not let MACD turn down.

1 · Reply

Gary9912 Jan. 14 at 3:16 AM

$ESPR The road from .70 to $4 wasn’t always smooth. I hope we didn’t lose anyone today becuase the future here never looked brighter. 💪💎

2 · Reply

___IFindKarma___ Jan. 14 at 3:13 AM

$ESPR This just in! New phase 1 trial results shows that Bempedoic Acid can add 20 years to your lifespan. 74 is the new 55! #WonderDrug

0 · Reply

Enjoyycall Jan. 14 at 2:55 AM

$ESPR Anyone else at JPM?

1 · Reply

OldManLogan Jan. 14 at 2:10 AM

$ESPR Once we get our EU royalties back and the JP royalties flow, I actually think they could fund a pretty excellent pipe... especially one focused on rare diseases (smaller trials, lower costs, accelerated approvals etc.) but I still say Vision 2040 is a 'show' to bargain for a better acquisition price... Sheldon is 60 years old for Crikey's sake... the dude is not hanging around until he's 74, lol. And no way is he magnanimous enough to do the heavy lifting only to hand it over to the next CEO on a silver platter...

0 · Reply

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Dec 9, 2025, 4:30 PM EST - 5 weeks ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nov 20, 2025, 4:03 PM EST - 7 weeks ago

Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 7:00 AM EST - 2 months ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Nov 12, 2025, 10:16 AM EST - 2 months ago

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

CCCC CWST INSP MNDY SITM

Nov 11, 2025, 9:31 PM EST - 2 months ago

Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript

Nov 10, 2025, 7:24 AM EST - 2 months ago

Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability

Nov 6, 2025, 2:06 PM EST - 2 months ago

Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 8:00 AM EST - 2 months ago

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Oct 27, 2025, 8:00 AM EDT - 2 months ago

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Oct 8, 2025, 8:01 AM EDT - 3 months ago

Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

JOBY PENG

Oct 7, 2025, 9:29 PM EDT - 3 months ago

Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 3 months ago

Esperion Announces Proposed Public Offering of Common Stock

Oct 3, 2025, 8:00 AM EDT - 3 months ago

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Sep 19, 2025, 8:00 AM EDT - 4 months ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Sep 7, 2025, 10:17 PM EDT - 4 months ago

Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 10:39 AM EDT - 4 months ago

Top 2 Health Care Stocks That May Plunge This Month

NUVB

Aug 29, 2025, 8:00 AM EDT - 4 months ago

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Aug 5, 2025, 10:10 AM EDT - 5 months ago

Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 6:00 AM EDT - 5 months ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 8:00 AM EDT - 6 months ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

Jul 1, 2025, 8:06 AM EDT - 7 months ago

Esperion Appoints Craig Thompson to Board of Directors

Jun 14, 2025, 7:03 AM EDT - 7 months ago

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?

May 12, 2025, 8:00 AM EDT - 8 months ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 9, 2025, 8:00 AM EDT - 8 months ago

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

May 8, 2025, 6:30 AM EDT - 8 months ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 6, 2025, 10:49 AM EDT - 9 months ago

Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript

Apr 25, 2025, 8:00 AM EDT - 9 months ago

Esperion to Participate in The Citizens Life Sciences Conference

Apr 24, 2025, 8:00 AM EDT - 9 months ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 10, 2025, 8:00 AM EDT - 9 months ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Apr 1, 2025, 8:00 AM EDT - 10 months ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Mar 4, 2025, 10:34 AM EST - 11 months ago

Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 6:00 AM EST - 11 months ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 11 months ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Feb 18, 2025, 8:00 AM EST - 11 months ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Dec 18, 2024, 7:00 AM EST - 1 year ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 14, 2024, 9:00 AM EST - 1 year ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

CRDF UI VOD DE FLNC GASS HII

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing

Dec 12, 2024, 8:00 AM EST - 1 year ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 8, 2024, 7:43 AM EST - 1 year ago

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Nov 18, 2024, 10:30 AM EST - 1 year ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Nov 13, 2024, 2:08 AM EST - 1 year ago

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Nov 7, 2024, 1:35 PM EST - 1 year ago

Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:00 AM EST - 1 year ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 4, 2024, 8:00 AM EST - 1 year ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Aug 26, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 9:10 AM EDT - 1 year ago

Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs

Rustyton Jan. 14 at 5:37 AM

1 · Reply

MoneyGroupLLC Jan. 14 at 5:23 AM

0 · Reply

littleguyfinance Jan. 14 at 5:15 AM

1 · Reply

Moneo Jan. 14 at 4:31 AM

$ESPR do I look scared MFer?

0 · Reply

Adam_W Jan. 14 at 4:24 AM

$ESPR Haven’t sold a single share….

0 · Reply

simbha Jan. 14 at 3:38 AM

$ESPR I am expecting this to bounce back to 3.61 by Friday. Back in the channel and not let MACD turn down.

1 · Reply

Gary9912 Jan. 14 at 3:16 AM

$ESPR The road from .70 to $4 wasn’t always smooth. I hope we didn’t lose anyone today becuase the future here never looked brighter. 💪💎

2 · Reply

___IFindKarma___ Jan. 14 at 3:13 AM

$ESPR This just in! New phase 1 trial results shows that Bempedoic Acid can add 20 years to your lifespan. 74 is the new 55! #WonderDrug

0 · Reply

Enjoyycall Jan. 14 at 2:55 AM

$ESPR Anyone else at JPM?

1 · Reply

OldManLogan Jan. 14 at 2:10 AM

0 · Reply

Gregg617 Jan. 14 at 1:12 AM

$ESPR looks like somebody had the same idea as me

1 · Reply

omar_progressivetrading Jan. 13 at 11:54 PM

$ESPR — We longs endure the ups and downs. Don’t sell for quick games, and don’t play games with your strategy. Many Moon Kids got slaughtered today by their own emotions. Some sold shares to chase options, thinking only about themselves, which is their right. But they have zero clue how that behavior impacts price structure and long-term momentum. Short-term ego, short-term thinking, short-term results. That’s fine with me. The long-term game always wins. Discipline always outlasts emotion. Strategy always outperforms impulse. Let the Moon Kids Show continue… To The Moon & Beyond! 🫡 🌓

2 · Reply

DragonAlgo Jan. 13 at 11:49 PM

🐉 $ESPR CALL — DragonAlgo® Signal Contract: ESPR CALL Expiry: 2026-01-16 | Strike: $4.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 System-defined risk profile. 🔗 https://dragonalgo.com

0 · Reply

Albertowest Jan. 13 at 11:25 PM

$ESPR you can check JPM presentation here https://www.esperion.com/investor-relations/events

0 · Reply

Gary9912 Jan. 13 at 10:38 PM

$ESPR Are Sheldon and crew trying to make this company more attractive for acquisition??? Because we all know they’re not gonna be able to go it alone until 2040 and fund research and fund more trials ( more dilution can’t work here). Let’s get the guidelines, payoff /settle with these remaining generics and get us our BO ( I know everyone has a different idea of what that is) and send everyone home happy here. I keep reading that biotech is due for another good year, and that there plenty of money for M&A with multiple pharma losing patents in the near future, have you seen some of the multiple billion companies are paying for smaller companies that aren’t even at market yet. Get it done Sheldon and don’t drag this out!

3 · Reply

Gregg617 Jan. 13 at 10:31 PM

$ESPR This is a win in my book started off the morning at the low of the day and the afternoon not entirely accurate because I sold 25,000 shares which should’ve been about an $8000 loss but still nice comeback

2 · Reply

travis305182 Jan. 13 at 10:26 PM

$ESPR one day closer to guidelines.

0 · Reply

PKinUK16 Jan. 13 at 10:26 PM

$ESPR I’m going to hold this for a long time but I am now worried its going to be this long 😂

0 · Reply

___IFindKarma___ Jan. 13 at 10:02 PM

$ESPR The new sales leader… https://www.linkedin.com/posts/johnharlowjr_that-is-the-look-of-a-man-whos-about-a-third-ugcPost-7416893818295324672-GhDm?utm_medium=ios_app&rcm=ACoAAAq9tVgBLVZvbbeGvh6G9LemOfJ4GbUK9EI&utm_source=social_share_send&utm_campaign=copy_link

0 · Reply

Albertowest Jan. 13 at 9:56 PM

$ESPR to all my fellow board members who are truly long and strong, you will heard and see almost every trick in the book regarding manipulation in the market and on all boards because we are very close!!! As long as shorts have their warrants and converts they can play with us and be in control but that doesn't mean shit, we know what we have PS my good old mate James at YF once told me (after I said DSE was killing it in 2024) that europeans were built different and that's why BA would never work in the US... EXPECT EVERYTHING FROM THEM, EVEN THE UNBELIAVIBLE Bullish

2 · Reply

BullDonald Jan. 13 at 9:53 PM

$ESPR Go on...

0 · Reply

biotech_expert Jan. 13 at 9:52 PM

$ESPR the last two day...

0 · Reply

Market Cap	848.67M
Revenue (ttm)	332.31M
Net Income (ttm)	-51.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	44.09
Profit Margin	-15.57%
Debt to Equity Ratio	-0.34

Volume	13,566,101
Avg Vol	6,310,836
Day's Range	N/A - N/A
Shares Out	239.06M
Stochastic %K	26%
Beta	1.04
Analysts	Strong Sell
Price Target	$6.46